Melqart Asset Management (Uk) LTD Cytokinetics Inc Transaction History
Melqart Asset Management (Uk) LTD
- $636 Million
- Q3 2025
A detailed history of Melqart Asset Management (Uk) LTD transactions in Cytokinetics Inc stock. As of the latest transaction made, Melqart Asset Management (Uk) LTD holds 783,774 shares of CYTK stock, worth $52.1 Million. This represents 6.78% of its overall portfolio holdings.
Number of Shares
783,774
Previous 1,326,719
40.92%
Holding current value
$52.1 Million
Previous $43.8 Million
1.73%
% of portfolio
6.78%
Previous 6.37%
Shares
7 transactions
Others Institutions Holding CYTK
# of Institutions
446Shares Held
135MCall Options Held
5.25MPut Options Held
1.18M-
T. Rowe Price Investment Management, Inc. Baltimore, MD19.1MShares$1.27 Billion0.64% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$975 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$788 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.41MShares$492 Million0.07% of portfolio
-
Paul Tudor Jones Tudor Investment Corp Et Al | Stamford, Ct6MShares$399 Million0.17% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $6.25B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...